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Background: Preliminary evidence suggests that palliative care may be useful for people with severe multiple sclerosis
(MS). The aim of this study is to determine the effectiveness of a home-based palliative approach (HPA) for people with
severe MS and their carers.
Methods/design: This is a single-blind randomized controlled trial with a nested qualitative study. Seventy-five severe
MS-carer dyads are being randomized (at three centers, one in each area of Italy) to HPA or usual care (UC) in a 2:1 ratio.
Each center has a specially trained team consisting of four professionals (physician, nurse, psychologist, social worker). The
team makes a comprehensive assessment of the needs of the dyads. HPA content is then agreed on, discussed with the
patient’s caring physician, and delivered over six months. The intervention is not intended to replace existing services. At
later visits, the team checks the HPA delivery and reviews/modifies it as necessary.
HPA and UC dyads are assessed at home by a blind examiner at baseline, and three and six months later; they
also receive monthly telephone interviews. Dyads assigned to UC receive the examiner’s visits and telephone
interviews, but not the team visits.
Primary outcome measures are changes in symptoms (Palliative care Outcome Scale-Symptoms-MS, POS-S-MS),
and quality of life (the Schedule for the Evaluation of Individual Quality of Life-Direct Weighting (SEIQoL-DW), not
assessed in patients with severe cognitive compromise) at three and six months. Other outcomes are changes in
patient functional status and mood; changes in carer quality of life, mood and caregiving burden; costs; incorporation
with standard care; unplanned hospital admissions; referrals to hospice; and deaths.
The experience of participants will be evaluated qualitatively by individual semi-structured interviews (HPA patients and
carers) and focus group meetings (HPA patients’ caring physicians).
Discussion: The results of our study will show whether the HPA is feasible and beneficial to people with severe MS and
their carers living in the three Italian geographic areas. The nested qualitative study will add to the understanding of the
strengths and limitations of the intervention.
Trial registration: The trial was registered with Current Controlled Trials (identifier: ISRCTN73082124) on 19 June 2014.
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Multiple sclerosis (MS) is the most common disabling
neurological condition of young adults in western coun-
tries. It affects over 2.5 million people worldwide, and evi-
dence suggests that incidence is increasing [1]. Around
15% of MS sufferers have a progressive course from the
outset (primary progressive MS), and a further 65% de-
velop progressive disease after a variable period with
relapsing-remitting disease (secondary progressive MS) [2].
For those with primarily or secondarily progressive MS,
treatment options to delay or prevent further clinical wors-
ening are limited. Reduced mobility and compromised
sphincter control are among the commonest symptoms,
but cognitive impairment, swallowing or speech impair-
ment, pain and sensory disturbances may also be promin-
ent [3-5]. Patients with severe MS are at risk of death from
aspiration pneumonia, urinary tract infections, complica-
tions of falls and fractures, and sepsis secondary to pres-
sure ulcers. Nevertheless, some highly disabled patients
live for many years, although most die in hospital rather
than at home [6].
Although robust evidence supporting treatment decisions
in advanced MS is lacking, recent guidelines suggest shift-
ing to a palliative approach as the disease worsens [7]. Pal-
liative care, with its focus on the physical, psychological,
spiritual and social needs of patients and families, and their
active involvement in medical decisions, aims to improve
the quality of care and reduce the use of emergency and
acute care services. However, palliative care has tradition-
ally been delivered in oncology, and is little used in MS and
other neurological diseases. There are issues that are spe-
cific to MS: for example, pain due to spasticity requires a
different approach to cancer pain management, and cogni-
tive and communication compromise may hamper ability
to reveal experiences and express choices. Furthermore, it
is difficult to anticipate life expectancy in people with severe
MS, who may sometimes need palliative care over an ex-
tended period.
It is noteworthy that recent studies on adults with severe
MS and their carers [8-11], and also newly diagnosed per-
sons with MS [12,13], indicated similar areas of concern
comprising insufficient time spent with health profes-
sionals, lack of information exchange, and discontinuity of
care.
The current trend of managing chronic and terminal
conditions in the community entails the need to imple-
ment effective home care models. Informal carers are an
essential source of support for MS patients, and in ad-
vanced disease informal carers take responsibility for
meeting most of their patient’s needs, thereby preventing
patient institutionalization. However, the caregiving bur-
den can lead to a decline in carers’ health-related quality
of life (HRQOL) and adversely affect their employment
and finances.Evidence supporting a benefit of palliative care is
sparse, with most studies assessing needs instead of in-
terventions, or having methodological flaws [14]. We
found two randomized controlled trials (RCTs) on the
efficacy of palliative care in people with severe MS
[8,15]. The UK trial showed that a home-based palliative
care service improved symptoms management, reduced
caregiver burden and the use of primary and acute hos-
pital services over the short term [8]. The Italian trial
(Ne-Pal) included people with severe MS, Parkinson’s
disease and related disorders, and amyotrophic lateral
sclerosis; the home-based palliative care intervention im-
proved patient HRQOL and some symptoms [15].
Nevertheless, it may not be straightforward to transfer
interventions of this sort to different contexts and health
systems [16,17].
Objectives
The primary aim of the present study is to determine
the effectiveness of a home-based palliative approach
(HPA) on MS symptoms and HRQOL of people with
severe MS. Secondary outcomes are changes in patient
functional status and mood; changes in carer HRQOL,
mood and caregiving burden; costs; incorporation with
standard care; unplanned hospital admissions; referrals
to hospice; and deaths over the six-month intervention.
Methods
Ethical approval and trial registration
The study was given ethical approval by the Foundation
IRCCS Neurological Institute ‘C. Besta’ (Besta internal
reference numbers 6, 11), the Foundation ‘S. Lucia’
Hospital (internal reference number CE/OSS.27), and
the University Hospital of Catania (internal reference
number 18/2014/PO) Ethics Committees. The trial is
registered with Controlled Clinical Trials (trial registra-
tion number ISRCTN73082124).
Trial design
This is a multicenter phase II/III single-blind randomized
controlled trial. Participants (dyads of adults with severe
MS and their carers) are randomized to either the HPA
intervention group or usual care (UC). Figure 1 presents
the PeNSAMI trial flowchart.
Inclusion and exclusion criteria
All adults (18 years or older) who fulfill all the follow-
ing criteria are potentially eligible:
(1)Diagnosis of MS [18]
(2)Expanded Disability Status Scale (EDSS) ≥8.0 [19]
(3)Primary or secondary progressive course
(4)Presence of a carer (family member, relative, or
friend, who is next of kin or is key decision maker
Figure 1 The PeNSAMI trial flowchart. *Visits 1 to 3 performed by a blind examiner; phone interviews performed by a trained
interviewer. HPA, home-based palliative approach; UC, usual care.
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patient and with whom the patient shares his/her
life)
(5)At least two unmet care needs among the
categories identified in the PeNSAMI Phase 1qualitative study (Table 1) [11], or the patient
declares for comfort care only
(6)One or more of the following: significant complex
symptoms/medical complications, dysphagia/poor
nutritional status, communication difficulties [20].
Table 1 List of main care need categories, as identified in
the PeNSAMI Phase 1 qualitative study [11]
Domain Category
‘Managing everyday life’ Symptoms management
Personal care/hygiene
Activities of daily living
Outdoor mobility and transport
‘Psychosocial’ Relationships/communication
Leisure/holidays
Psychological well-being/social role
‘Organization’ Information
Access to services
Co-ordination of services
Competent professionals
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(1)Hospitalized/institutionalized patients
(2)Patients already receiving palliative care
(3)Dyads living out of study area
Recruitment
Starting on 10 January 2015 participants are being re-
cruited from the three participating centers. Recruitment
closes at the end of June 2015.
Informed consent and pre-study evaluation (Visit 0)
Potentially eligible patients are identified by the center
principal investigator (PI) by consulting the MS center
database and by contacts with general practitioners (GPs),
and other health personnel involved in the care of severely
affected MS patients. MS patient and their carer are
approached by a HPA team member to give informed con-
sent to participate. If consent is obtained, baseline elec-
tronic case record forms (eCRFs) are completed.
Baseline visit (Visit 1)
After pre-study evaluation, participants identified as
meeting the eligibility criteria are assessed at home by
the blind examiner who confirms the inclusion criteria,
administers the outcome instruments and initiates the
randomization procedure. A card showing the time and
date of the three- and six-month follow-up visits is given
to the dyad.
Randomization
Eligible study participants are randomized to either
HPA or UC using third-party, web-based computerized
randomization software. A stratified minimization algo-
rithm is used to ensure balance of possible prognostic
factors across the two groups (EDSS (8.0 to 8.5, 9.0 to
9.5), presence of severe cognitive compromise (clinicaljudgment), and center (Milan, Rome, Catania)). Follow-
ing randomization, an email informing on dyad assign-
ment is sent to the PI and the HPA team. The team
informs the dyad about assignment. The team also con-
tacts the patient’s caring physician (GP, neurologist or
other physician responsible for the patient’s care) to in-
form him/her about the study and (for dyads assigned
to HPA) define a common agenda.
Blinding
To reduce measurement bias, the baseline and follow-up
assessments are performed by independent examiners
blind to treatment assignment (one examiner plus
backup at each center, both trained, neither involved in
HPA delivery). Prior to each follow-up visit, study dyads
will be reminded not to disclose their allocation by men-
tioning any contact with the HPA team to the blind
examiner. The examiner will be asked to guess dyad sta-
tus (HPA vs. UC) after the three- and six-month visits to
assess whether blinding is maintained.
HPA group
The trial intervention is based on the principles of pallia-
tive care as described in the 2010 guidance document of
the UK National Council for Palliative Care, Neurological
Alliance, and National End of Life Care Programme [21].
Each center has a HPA team consisting of four profes-
sionals: a physician (neurologist, physiatrist or palliative
specialist), nurse, psychologist, and social worker. The
HPA team nurse is the case manager and team leader: the
nurses of the centers of Milan and Rome have degrees in
palliative care; the Catania nurse attended a FARO Foun-
dation week-long individual training course in September
2014. All HPA team members were trained in the HPA
intervention at the FARO Foundation, Turin, 20 to 21
February 2014. HPA teams will meet about two months
after trial initiation (more often if necessary) to share ex-
periences and fine-tune the protocol.
Each HPA team meets regularly to discuss the manage-
ment of dyads in their charge. Initially, the team forms a
comprehensive assessment of each dyad based on infor-
mation provided by the blind examiner visit (available to
the HPA team via the eCRF and the web-based informa-
tion system) and that provided by the team home visit.
The HPA content for each dyad is then developed, dis-
cussed with the caring physician, and delivered over six
months, with involvement of local services. The interven-
tion is not intended to replace existing services but to
complement and enhance them, minimizing duplication
of effort. Subsequently, the HPA team verifies program
implementation, and reviews and modifies it as necessary.
Home visits by one or more team members will take
place at least twice a month in the first trimester, and as
needed thereafter. Which professionals attend for home
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symptoms (for example physician for pain management,
nurse for bed sore treatment). A dedicated phone num-
ber is given to dyads to enable easy communication with
the HPA team. The team is not on call for patients: in
the event of emergencies, dyads contact the caring phys-
ician or emergency medical services.
We expect HRQOL and other study outcomes to im-
prove in the first trimester, so thereafter frequent home
visits could be useless or intrusive [15]. However, if symp-
toms and HRQOL worsen, or end of life issues manifest,
intensity of care will be maintained or increased. All HPA
team activities/interventions will be recorded in the pa-
tient study record, kept at the patient’s home and available
to all health professionals/caregivers. To preserve blinding,
before visits 2 and 3, dyads will be reminded to keep the
patient study record out of the blind examiner’s sight (for
example by placing it in a drawer).
UC group
UC consists of the health and social services normally
provided by the Italian National Health Service in the
study area (for example by GP, district nursing service,
social services, neurologists and other specialists, and
emergency services). Patient-carer dyads assigned to UC
receive the three blind examiner visits and the monthly
telephone interviews, but not the HPA team visits (ex-
cept Visit 0). At the end of the study, dyads who re-
ceived UC will be offered the HPA.
Primary outcomes
Primary outcomes are changes in patient HRQOL (Sched-
ule for the Evaluation of Individual Quality of Life-Direct
Weighting, SEIQoL-DW) and MS symptoms (Palliative
care Outcome Scale-Symptoms-MS, POS-S-MS). The
SEIQoL-DW is a brief instrument, derived from the sched-
ule for evaluation of individual quality of life (SEIQoL). It
allows respondents to nominate areas of life that are most
important in determining their HRQOL. The level of satis-
faction/functioning in each of these areas is then recorded
[22-26]. The SEIQoL-DW index is obtained from the satis-
faction with and weighting for each area, and ranges from 0
(worst possible score) to 100 (best possible score). SEIQoL-
DW has been used in neurological diseases [27-30], and
was the primary outcome measure of the Ne-Pal trial [15].
POS-S-MS (primary outcome measure) and the Core-
Palliative care Outcome Scale (Core-POS) were developed
and validated for use with palliative care patients to assess
emotional, psychological and spiritual needs, and provision
of information and support [31,32]. Core-POS has been
used in patients with advanced cancer and other conditions
including dementia, motor neuron disease, and MS [33,34].
It consists of 10 items, which are scored from 0 (best) to 4
(worst). The score is the sum of the scores from eachquestion, and therefore can range from 0 to 40. There are
patient, carer, and staff versions, each requiring about 10
minutes to complete [31,35]. Generally, the patient is asked
about needs over the preceding three days, but other time
frames have been used [36]: in this study, we asked about
the preceding seven days.
POS-symptoms (POS-S) is a scale enquiring about 10
symptoms with two open questions (which symptom af-
fected the patient the most; which improved most). It was
developed for use in cancer patients and is used alongside
the Core-POS for assessing common physical symptoms.
Disease-specific versions of POS-S have been developed
for end-stage kidney disease, Parkinson’s disease, and MS
[33]. POS-S-MS comprises 18 items relating to MS symp-
toms, plus an open question (0 to 4 scale) over the preced-
ing seven days [34].
The psychometric properties of Core-POS and POS-S-MS
have been assessed in patients with severe MS: both are
acceptable, reliable, and valid in this population [34].
In the present RCT, MS patients with severe cognitive
impairment do not complete the questionnaires: the care-
giver versions of Core-POS and POS-S-MS are used.
Secondary outcomes
Secondary outcome measures are HRQOL as assessed
by Core-POS [34] and European Quality of Life Five Di-
mensions (EQ-5D) [37,38]; mood as assessed by the
Hospital Anxiety and Depression Scale (HADS) [39,40];
impairment/activity limitations as assessed by EDSS [19]
and Functional Independence Measure (FIM) [41,42];
and direct and indirect tangible costs are assessed by the
MS foundation Costs Questionnaire (MSCQ) [43].
Carer outcomes are: HRQOL as measured by Short
Form 36 (SF-36) [44,45] and EQ-5D; mood as measured
by the HADS; and carer burden as measured by the
Zarit Burden Interview (ZBI) [46,47].
Recruitment rates, reasons for exclusion, time to delivery
of interventions, adherence to intervention (see the HPA
group), protocol deviations, incorporation with standard
care, unplanned hospital admissions, referrals to hospice,
deaths (place and cause) are also considered over the six-
month period.
Outcome assessments (Table 2) are carried out at
baseline, and after three and six months, by a blind
examiner at the patient’s home. In addition, six tele-
phone interviews are performed, on a monthly basis, by
a trained interviewer who administers the full MSCQ (at
three and six months) and pertinent MSCQ sections (at
one, two, four and five months).
Safety
We expect no serious psychological, physical, social,
or legal risks to derive from exposure to the study
intervention. We cannot exclude, however, that the
Table 2 Outcome measures and timing of follow-up
Baseline Three-month
follow-up
Six-month
follow-up
General characteristics X X X
MS history X X X
Medical history X X X
EDSS X X X
FIM X X X
SEIQoL-DW* X X X
Core-POS** X X X
POS-S-MS** X X X
HADS* X X X
EQ-5D* X X X
MSCQ X † †
Carer characteristics /medical
history
X X X
Carer HADS X X X
Carer SF-36 X X X
Carer EQ-5D X X X
Carer ZBI X X X
To preserve blinding, all outcome measures (except MSCQ) are assessed during
examiner visits at three and six months follow-up. *Not assessed in MS patients
with severe cognitive compromise or unable to communicate; **carer
versions used in MS patients with severe cognitive compromise or unable
to communicate; †assessed by phone interview. Core-POS, Core-Palliative
care Outcome Scale; EDSS, Expanded Disability Status Scale; EQ-5D, European
Quality of Life Five Dimensions; FIM, Functional Independence Measure; HADS,
Hospital Anxiety and Depression Scale; MSCQ, Multiple Sclerosis foundation Costs
Questionnaire; MS, multiple sclerosis; POS-S-MS, Palliative care Outcome
Scale-Symptoms-Multiple Sclerosis; SF-36, Short Form 36; SEIQoL-DW, Schedule
for the Evaluation of Individual Quality of Life-Direct Weighting; ZBI, Zarit
Burden Interview.
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status. The following serious adverse events (SAEs) are be-
ing monitored:
– Emergency room visits that do not result in hospital
admission
– Hospitalizations (overnight stay at hospital or
emergency room for observation or treatment)
– Death (any cause)
Hospitalization for elective surgery, routine or planned
clinical procedures are not considered SAEs.
Withdrawals and loss to follow-up
Dyads can withdraw from the study at any time. The
‘intention-to-treat’ principle will apply for participants
who withdraw or are lost to follow-up.
Independent data and safety monitoring committee
(IDSMC)
The IDSMC monitors SAE reports throughout the trial,
and oversees trial progress, ensuring that it is conducted,recorded, and reported in accordance with the protocol,
good clinical practice, and applicable regulatory require-
ments. The IDSMC provides recommendations about
stopping or continuing the trial in the event of harm,
undue risks, or futility. IDSMC members (Appendix 1)
met (via teleconference) prior to the start of enrolment.
Subsequent IDMSC teleconferences are scheduled every
four months, and at trial termination, or more frequently
as necessary.
Sample size
The sample size was based on previous data for SEIQoL-
DW [15] and POS-S-MS [8]; for both outcomes we con-
sidered changes at three months compared to baseline.
SEIQoL-DW: a sample size of 21 patients assigned to
HPA (study intervention) and 11 assigned to UC (con-
trol) has a power of 80% to detect an assumed mean
change of score of 31.5 (standard deviation (SD) 12.8) in
the HPA group compared to a change of 12.1 (SD 19.3)
(null hypothesis) in the UC group, at alpha level 0.05
using a two-sided, two-sample t test. Assuming 20%
dropout, 25 patients are required in the HPA group and
13 in the UC group (total sample size 38).
POS-S-MS: a sample size of 41 HPA and 21 UC has a
power of 85% to detect an assumed mean change of
−0.4 (SD 0.5) in the HPA group, with a concomitant
change of 0.2 (SD 0.8) (null hypothesis) in the UC group;
assuming an alpha level of 0.05 and a two-sided, two-
sample t test. Assuming 20% dropout, 49 patients are re-
quired in the HPA group and 25 patients in the UC
group (total sample size 74).
It is expected that up to 50% of MS patients have se-
vere cognitive compromise, and will not be able to
complete SEIQoL-DW, in these the only primary end-
point will be the POS-S-MS. We aim to recruit 50 pa-
tients in the HPA group and 25 patients in the UC
group, thereby achieving an exact 2:1 ratio of interven-
tion to control.
Statistical analyses
Continuous data will be summarized using means, me-
dians, SDs, minimums and maximums. Between-group
comparisons will employ either the two-sided unpaired t
test or Wilcoxon’s two-sided two-sample test for non-
normal data. Distributions will be tested for normality
using the Shapiro-Wilk test. Correlations will be esti-
mated using Spearman’s or Pearson’s coefficients. Cat-
egorical data will be compared by χ2 or Fisher’s exact
test.
Longitudinal changes in SEIQoL-DW and POS-S-MS
will be analyzed using linear mixed models for longitudinal
data [48,49]. All tests will be two-tailed. P values <0.05 will
be considered significant. For the primary intention-to-treat
analyses, multiple imputation of missing values will employ
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Stata Statistical Software, release 12 (StataCorp LP, College
Station, TX, USA), or SAS, release 9.2 (SAS Institute Inc.,
Cary, NC, USA).Nested qualitative study
The qualitative study consists of two parts: personal,
semi-structured interview with MS patients and carers,
and focus group meetings (FGMs) of patients’ caring
physicians. The aim is to evaluate the experience of par-
ticipants in order to gain insights into the strengths and
weaknesses of the HPA.Informed consent
Prior to participation, potentially eligible qualitative study
participants (patients and carers who received the HPA
and caring physicians of patients) will be approached by
the center PI or a HPA team member, and asked to pro-
vide informed consent to participate.Personal semi-structured interviews
We will use a purposive sampling technique to identify
consenting HPA dyads in whom primary outcomes (SEI-
QoL-DW and POS-S-MS) were either among the highest
or lowest of the distribution, at the three- or six-month
follow-ups. For the dyads thus identified, patients and
carers will be interviewed separately, within six months of
trial completion. Interviews will be face-to-face, conducted
by a trained psychologist in the patient’s home, last for a
maximum of 60 minutes (patients) or 90 minutes (care-
givers), and will be audio-recorded and transcribed in full.
Interviewees will be asked about the acceptability and util-
ity of the HPA intervention as a whole and other issues
that arise or seem pertinent (for example relation with
professionals, timing, integration with current care).
The interviewer will also note participant behavior
and other potentially useful non-verbal aspects that
emerge. Only carers will be interviewed if the patient
has severe cognitive compromise. A minimum of 12
dyads (four at each center) will be included, with sam-
pling continuing until no new themes emerge from
the data (data saturation) [50].Focus group meetings
Three FGMs will be conducted (one at each center),
their objective is to reveal physicians’ experiences and
views about the study intervention. Positive and nega-
tive aspects will be solicited. All caring physicians of
patients who received the HPA will be invited to par-
ticipate. Each FGM will be audio-recorded, has a mod-
erator (a trained psychologist) and co-moderator, and
an expected minimum of five physician participants.Analysis
The methods of framework analysis [50-52] will be ap-
plied to the data. Framework analysis uses a systematic
approach to analyzing the content of interviews and
FGMs, to thereby identify themes and categories of re-
sponses. The interviewers/moderators will review the
audio recordings and written notes, and produce inter-
view/meeting transcripts. Interviews and FGMs will be
analyzed in successive steps, each corresponding to an
increasing level of generalization [53]. Two researchers
will analyze the interviews and FGMs, first independ-
ently and then jointly. Each FGM report will be submit-
ted to FGM participants for review (respondent
validation). The interview and FGM reports will then be
considered jointly to produce a more comprehensive
analysis of the data (triangulation) [54].
Study organization
The study investigators/committees are reported in Appen-
dix 1. The trial steering committee is the main decision-
making body. It consists of local PIs, patient and consumer
representatives, and experts in MS, palliative care, rehabili-
tation, and methodology. The steering committee meets at
least once a year and is the study writing committee (on be-
half of all investigators).
The IDSMC is chaired by a palliative physician, and
includes a neurologist and methodologist. The IDSMC
met (via teleconference) before starting accrual; subse-
quent teleconferences are scheduled every four months,
and at trial termination. IDSMC reports are sent to the
trial steering committee.
The qualitative study panel is responsible for plan-
ning, conducting and analyzing the qualitative study.
It consists of two psychologists with expertise in quali-
tative research, and the psychologists who will con-
duct interviews and FGMs.
Trial data are entered into a web-based, password-
protected data management system/eCRF that permits
edit-audit trails (by authorized trained personnel). Paper
copies of eCRFs and any (anonymized) supporting docu-
mentation is stored securely at participating centers,
with identifying contact details and signed consent forms
stored separately, for seven years.
Discussion
PeNSAMI is a RCT with a nested qualitative study de-
signed to test the effectiveness of a HPA on people with
severe MS and their carers. This trial will primarily as-
sess the effect of the HPA on patient HRQOL and symp-
toms; secondarily it will assess patient functional status
and mood; carer HRQOL, mood and caregiving burden;
costs, incorporation with standard care, unplanned hos-
pital admissions, referrals to hospice, and deaths over
the six-month period.
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palliative approach to people with severe MS that adopts
a single-blind (examiner) and multicenter design. By also
evaluating the experiences of the key players involved in
the HPA, we will better identify intervention strengths
and limitations. Integration of these qualitative findings
with the quantitative findings will maximize possibilities
for improving the HPA [55]. Additionally, careful docu-
mentation of the content, processes and outcomes of the
intervention will make possible its replication and wide
implementation [55].
We decided on a randomized controlled study because
of its potential to produce unbiased data on intervention
efficacy. UC was considered the most suitable compara-
tor, since a sham intervention was not feasible. Note,
however, that regular outcome assessment with frequent
contacts ensures that the control group receives a con-
siderable amount of attention. For ethical reasons and to
encourage participation, we decided to assign eligible
dyads to HPA vs. UC in a 2:1 ratio, and also to offer con-
trol dyads the HPA at the end of follow-up.Expected benefits
Fragmentation of care across different health care sectors
is a recognized problem, particularly for patients with
complex care needs and co-morbidities. The HPA is not
intended to replace existing services but to complement,
collaborate with, and enhance them, minimizing duplica-
tion of effort. The potential for HPA integration into exist-
ing services is a strength of our trial.
Health professionals caring for people with severe
MS themselves have several unmet needs and feel over-
stretched in their daily work. Physicians express feel-
ings of helplessness or anger in the face of cuts in
funding, and having to work under time pressure and
in complex social situations [11]. They also feel ham-
pered by inadequate communication skills (not taught
at university) [10,56].
In addition to providing valuable data, the trial affords
interdisciplinary training for the health professionals in-
volved. By making palliative care professionals work with
MS neurology and rehabilitation professionals [57], the
trial should encourage greater awareness and more ef-
fective management of people with severe MS.
Effective exchange between the dyad, the caring phys-
ician and the HPA team should result in treatment deci-
sions in the best interests of MS patients and the
avoidance of inappropriate hospital admissions. It is also
expected that the trial will empower people with severe
MS (and their carers) by providing them with informa-
tion and education on their condition, encouraging them
to be active participants in care and decision making, in-
cluding advance health directives where appropriate.Limitations and concerns
We estimated a sample size of 75 patients, which is ra-
ther small for a phase II/III trial. We based our sample
size estimate on published data: for POS-S-MS, these
data come from MS patients with similar characteristics
to our study population [8], and for SEIQoL-DW, from
people with severe MS or other neurodegenerative con-
ditions [15]. In view of our limited sample size, we used
adaptive (minimization) randomization to ensure com-
parability of study arms.
Another limitation is that, in contrast with previous
trials [8,15], our trial did not originate from palliative
services, which in theory can directly address needs
identified. Our HPA aims to activate existing services or
bring them to the attention of the dyad. The extent to
which these aims are achieved cannot be predicted.
Finally, having a blind examiner renders trial proce-
dures considerably more complex: the blind examiner
must have no contact with the HPA team; dyads must
be briefed about the importance of keeping the examiner
blinded; and, prior to three- and six-month visits, the
blind examiner is instructed to caution dyads against
disclosing their assignment or mentioning issues related
to study procedures. In addition, costs and intensity of
care outcomes, as assessed by the MSCQ, are assessed
by telephone interviews at three and six months con-
ducted by an independent professional - again to prevent
examiner unmasking.Trial status
Patient recruitment started in January 2015.Appendix 1
PeNSAMI project investigators.
Steering Committee: R Amadeo, A Giordano, M Ponzio,
MG Grasso, A Lugaresi, F Patti, G Martino, L Palmisano,
S Veronese, P Zaratin, MA Battaglia, A Solari.
Data Management and Analysis Committee: A Giordano,
D Radice (statistician): Division of Epidemiology and Bio-
statistics, European Institute of Oncology, Milan, M Ponzio
(statistician), G Ferrari, A Solari.
Independent Data and Safety Monitoring Committee:
DJ Oliver: Wisdom Hospice, University of Kent, Rochester,
Kent, UK; E Pucci: Neurology Unit, Ospedale Provinciale
di Macerata, Macerata; L Tesio: Department of Biomed-
ical Sciences for Health, University of Milan, Milan.
Qualitative Analysis Panel: E Bianchi, E Pietrolongo, A
Solari, A Giordano, I Rossi, S Cilia, M Giuntoli, C Borreani.
Literature Review Panel: MG Grasso, L Palmisano, A
Fittipaldo, A Giordano.
Intervention Panel: C Cugno, R Causarano, P Morino:
‘Ex Convento delle Oblate’ Hospice, Local Health Unit of
Florence, Florence, S Veronese.
Solari et al. Trials  (2015) 16:184 Page 9 of 10Centers and Investigators: AISM Liguria Region Re-
habilitation Service, Genoa: ML Lopes de Carvalho, M
Giuntoli, R Motta, MA Battaglia; Antea Charitable
Association, Rome: G Casale, MC Stefanelli; FARO
Charitable Foundation, Turin: S Veronese, C Cugno;
Foundation IRCCS Istituto Nazionale per la Cura dei
Tumori, Milan: C Borreani, E Bianchi; Foundation
IRCCS Neurological Institute C Besta, Milan: A Solari, P
Confalonieri, A Giovannetti, V Torri Clerici, E Rossetti,
A Totis, A Campanella, A Giordano, F Martini, A
Fittipaldo, G Ferrari, R Mantegazza; Foundation IRCCS
S Lucia Rehabilitation Hospital, Rome: MG Grasso, I
Rossi, E Troisi, A Pompa, L Tucci, F Ippoliti, G Morone,
A Fusco; Istituto Superiore di Sanità, Rome: L Palmisano;
Associazione Italiana Sclerosi Multipla (AISM), Genoa:
R Amadeo, G Martino; Fondazione Italiana Sclerosi Multipla
(FISM), Genoa: P Zaratin, M Ponzio, MA Battaglia;
Niguarda Ca’ Granda Hospital, Milan: R Causarano, D
Da Col, B Lissoni; G d’Annunzio University, Chieti-Pescara,
Chieti: A Lugaresi, E Pietrolongo, M Onofrj; University
Hospital Policlinico Vittorio Emanuele, Catania: F Patti, S
Cilia, C Leone, V Cascio, V Cimino, G Occhipinti, A
Pappalardo, C Cavallaro, F Zagari.
Abbreviations
Core-POS: Core-Palliative care Outcome Scale; eCRF: electronic case record
form; EDSS: Expanded Disability Status Scale; EQ-5D: European Quality of Life
Five Dimensions; FGM: focus group meeting; FIM: Functional Independence
Measure; GP: general practitioner; HADS: Hospital Anxiety and Depression
Scale; HPA: home-based palliative approach; HRQOL: health-related quality
of life; IDSMC: Independent Data and Safety Monitoring Committee;
MSCQ: Multiple Sclerosis foundation Costs Questionnaire; MS: multiple
sclerosis; PI: principal investigator; POS-S-MS: Palliative care Outcome
Scale-Symptoms-Multiple Sclerosis; RCT: randomized controlled trial;
SAE: serious adverse event; SD: standard deviation; SF-36: Short Form 36;
SEIQoL-DW: Schedule for the Evaluation of Individual Quality of Life - Direct
Weighting; UC: usual care; ZBI: Zarit Burden Interview.
Competing interests
AS has been a board member of Biogen Idec and Novartis, and has received
speaker honoraria from Genzyme, Merck Serono, the Fondazione Serono and
Excemed. MGG has received research funding from Merck Serono and
consulting and speaking fees from Biogen Idec. PC has been a board
member of Biogen Idec, received travel grants from Sanofi Aventis, Biogen
Dompe’ and Merk Serono. FP received honoraria for speaking activities from
Bayer Schering, Biogen Idec, Merck Serono, Novartis, and Sanofi Aventis. He
has served as advisory board member of the following companies: Bayer
Schering, Biogen Idec, Merck Serono, and Novartis. AL has been a Bayer
Schering, Biogen Idec, Merck Serono and Genzyme advisory board member.
She received travel grants and honoraria from Bayer Schering, Biogen Idec,
Merck Serono, Novartis, Sanofi Aventis and Teva and research grants from
Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi Aventis and Teva.
She has also received travel and research grants from the Associazione
Italiana Sclerosi Multipla and was a consultant of Fondazione Serono. LP, RA,
and MAB are board members of the Fondazione Italiana Sclerosi Multipla
(charitable organization). All other authors declare that they have no
competing interests.
Authors’ contributions
AS, PZ, and MAB conceived the study. AS, AG, and CB designed the study.
MGG, PC, FP, AL, LP, RA, GM, MP, GC, RC, and SV contributed to the study
design. AS and AG drafted the first version of this manuscript. MGG, PC, FP,
AL, LP, RA, GM, MP, GC, CB, RC, SV, PZ, and MAB critically reviewed themanuscript for intellectual content. All authors read and approved the final
manuscript.
Acknowledgements
The study is funded by the Fondazione Italiana Sclerosi Multipla (grant no.
2014/S/1 to AS). The funding source played no role in the study design, and
will play no role in the collection, analysis, and interpretation of data, the
writing of the manuscript or the decision to submit the manuscript for
publication.
We thank the contract research organization Yghea for eCRF setup, testing
and maintenance, and for help with the submissions to the ethics
committees of the participating centers. We also thank Don Ward for help
with the English.
Author details
1Unit of Neuroepidemiology, Foundation IRCCS Neurological Institute C.
Besta, Via Celoria 11, 20133 Milan, Italy. 2Multiple Sclerosis Unit, Foundation
IRCCS S. Lucia Rehabilitation Hospital, Via Ardeatina 306, 00179 Rome, Italy.
3Unit of Neuroimmunology, Foundation IRCCS Neurological Institute C. Besta,
Via Celoria 11, 20133 Milan, Italy. 4Department of Medical and Surgical
Sciences and Advanced Technologies, University of Catania; MS Center,
Neurology Clinic, University Hospital Policlinico Vittorio Emanuele, Via Santa
Sofia 78, 95123 Catania, Italy. 5Department of Neuroscience, Imaging and
Clinical Sciences, G. d’Annunzio University of Chieti-Pescara, Via dei Vestini
31, 66100 Chieti, Italy. 6Department of Therapeutic Research and Medicine
Evaluation, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome,
Italy. 7Associazione Italiana Sclerosi Multipla, Via Operai 40, 16149 Genoa,
Italy. 8Fondazione Italiana Sclerosi Multipla, Via Operai 40, 16149 Genoa, Italy.
9Antea Charitable Association, Piazza Santa Maria della Pietà 5, 00135 Rome,
Italy. 10Unit of Clinical Psychology, Foundation IRCCS Istituto Nazionale per la
Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy. 11Unit of Palliative
Care-Hospice, Niguarda Ca’ Granda Hospital, Piazza Ospedale Maggiore 3,
20162 Milan, Italy. 12FARO Charitable Foundation, Via Morgari 12, 10125 Turin,
Italy.
Received: 20 January 2015 Accepted: 30 March 2015
References
1. Alonso A, Hernán MA. Temporal trends in the incidence of multiple
sclerosis: a systematic review. Neurology. 2008;71:129–35.
2. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502–17.
3. Gruenewald DA, Higginson IJ, Vivat B, Edmonds P, Burman RE. Quality of life
measures for the palliative care of people severely affected by multiple
sclerosis: a systematic review. Mult Scler. 2004;10:690–704.
4. Higginson IJ, Hart S, Silber E, Burman R, Edmonds P. Symptom prevalence
and severity in people severely affected by multiple sclerosis. J Palliat Care.
2006;22:158–65.
5. Giordano A, Ferrari G, Radice D, Randi G, Bisanti L, Solari A, et al. Self-assessed
health status changes in a community cohort of people with multiple sclerosis:
11 years of follow-up. Eur J Neurol. 2013;20:681–8.
6. Campbell CW, Jones EJ, Merrills J. Palliative and end-of-life care in advanced
Parkinson’s disease and multiple sclerosis. J Clin Med. 2010;10:290–2.
7. National Institute for Health and Clinical Excellence. Multiple sclerosis.
Management of multiple sclerosis in primary and secondary care. NICE
clinical guideline 186. http://www.nice.org.uk/guidance/cg186/resources/
guidance-multiple-sclerosis-pdf. Accessed 15 January 2015.
8. Edmonds P, Hart S, Wei G, Vivat B, Burman R, Silber E, et al. Palliative care
for people severely affected by multiple sclerosis: evaluation of a novel
palliative care service. Mult Scler. 2010;16:627–36.
9. Galushko M, Golla H, Strupp J, Karbach U, Kaiser C, Ernstmann N, et al.
Unmet needs of patients feeling severely affected by multiple sclerosis in
Germany: a qualitative study. J Palliat Med. 2014;17:274–81.
10. Golla H, Galushko M, Pfaff H, Voltz R. Multiple sclerosis and palliative
care - perceptions of severely affected multiple sclerosis patients and
their health professionals: a qualitative study. BMC Palliat Care.
2014;13:11. doi:10.1186/1472-684X-13-11.
11. Borreani C, Bianchi E, Pietrolongo E, Rossi I, Cilia S, Giuntoli M, et al. Unmet
needs of people with severe multiple sclerosis and their carers: qualitative
findings for a home-based intervention. PLoS One. 2014;9:e109679.
doi:10.1371/journal.pone.0109679.
Solari et al. Trials  (2015) 16:184 Page 10 of 1012. Heesen C, Kasper J, Segal J, Köpke S, Mühlhauser I. Decisional role
preferences, risk knowledge and information interests in patients with
multiple sclerosis. Mult Scler. 2004;10:643–50.
13. Solari A, Acquarone N, Pucci E, Martinelli V, Marrosu MG, Trojano M, et al.
Communicating the diagnosis of multiple sclerosis - a qualitative study. Mult
Scler. 2007;13:763–9.
14. Zimmermann C, Riechelmann R, Krzyzanowska M, Rodin G, Tannock I.
Effectiveness of specialized palliative care: a systematic review. JAMA.
2008;299:1698–709.
15. Veronese S, Oliver D. Methodology of the quantitative study. In: Veronese S,
Oliver D, editors. Palliative care for people with neurodegenerative
conditions. Saarbrucken: Lambert Academic Publishing;
2013. p. 281–300.
16. Stjernwärd J, Foley K, Ferris F. The public health strategy for palliative care.
J Pain Symptom Manage. 2007;33:486–93.
17. Voltz R. Palliative care for multiple sclerosis: a counter-intuitive approach?
Mult Scler. 2010;16:515–7.
18. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al.
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald
criteria. Ann Neurol. 2011;69:292–302.
19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded
disability status scale (EDSS). Neurology. 1983;33:1444–52.
20. Prognostic Indicator Guidance (PIG). 2011. http://www.goldstandards
framework.org.uk/cd-content/uploads/files/General%20Files/Prognostic%20
Indicator%20Guidance%20October%202011.pdf. Accessed 15 Jan 2015.
21. End of life care in long term neurological conditions: a framework for
implementation. 2011. http://www.mssociety.org.uk/sites/default/files/
Documents/Professionals/End%20life%20care%20long%20term%20neuro%
20conditions.pdf. Accessed 15 Jan 2015.
22. McGee HM, O’Boyle CA, Hickey A, O’Malley K, Joyce CR. Assessing the
quality of life of the individual: the SEIQoL with a healthy and a
gastroenterology unit population. Psychol Med. 1991;21:749–59.
23. O’Boyle CA, McGee H, Hickey A, O’Malley K, Joyce CR. Individual quality of
life in patients undergoing hip replacement. Lancet. 1992;339:1088–91.
24. O’Boyle CA, McGee HM, Hickey A, Joyce CRB, Browne J, O’Malley K, et al.
The Schedule for the Evaluation of Individual Quality of Life (SEIQoL).
Administration manual. Dublin: Royal College of Surgeons in Ireland; 1993.
25. Hickey AM, Bury G, O’Boyle CA, Bradley F, O’Kelly FD, Shannon W. A new
short form individual quality of life measure (SEIQoL-DW): application in a
cohort of individuals with HIV/AIDS. BMJ. 1996;313:29–33.
26. Wettergren L, Kettis-Lindblad A, Sprangers M, Ring L. The use, feasibility and
psychometric properties of an individualised quality-of-life instrument: a
systematic review of the SEIQoL-DW. Qual Life Res. 2009;18:737–46.
27. Lee MA, Walker RW, Hildreth AJ, Prentice WM. Individualized assessment of
quality of life in idiopathic Parkinson’s disease. Mov Disord. 2006;21:1929–34.
28. LeVasseur SA, Green S, Talman P. The SEIQoL-DW is a valid method for
measuring individual quality of life in stroke survivors attending a secondary
prevention clinic. Qual Life Res. 2005;14:779–88.
29. Chiò A, Gauthier A, Montuschi A, Calvo A, Di Vito N, Ghiglione P, et al. A
cross sectional study on determinants of quality of life in ALS. J Neurol
Neurosurg Psychiatry. 2004;75:1597–601.
30. Pollmann W, Busch C, Voltz R. Quality of life in multiple sclerosis: measures,
relevance, problems, and perspectives. Nervenarzt. 2005;76:154–69.
31. Hearn J, Higginson IJ. Development and validation of a core outcome
measure for palliative care: the palliative care outcome scale. Palliative care
core audit project advisory group. Qual Health Care.
1999;8:219–27.
32. Higginson IJ, Donaldson N. Relationship between three palliative care
outcome scales. Health Qual Life Outcomes. 2004;2:68–75.
33. Bausewein C, Le Grice C, Simon S, Higginson I. PRISMA: the use of two
common palliative outcome measures in clinical care and research: a
systematic review of POS and STAS. Palliat Med. 2011;25:304–13.
34. Sleeman KE, Higginson IJ. A psychometric validation of two brief measures
to assess palliative need in patients severely affected by multiple sclerosis.
J Pain Symptom Manage. 2013;46:406–12.
35. Harding R, Higginson IJ, Donaldson N. The relationship between patient
characteristics and carer psychological status in home palliative cancer care.
Support Care Cancer. 2003;11:638–43.
36. Horton R. Differences in assessment of symptoms and quality of life
between patients with advanced cancer and their specialist palliative care
nurses in a home care setting. Palliat Med. 2002;16:488–94.37. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status:
results from a United Kingdom national questionnaire survey. BMJ.
1998;316:736–41.
38. Johnson JA, Coons SJ, Ergo A, Szava-Kovats G. Valuation of EuroQOL
(EQ-5D) health states in an adult US sample. Pharmacoeconomics.
1998;13:421–33.
39. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta
Psychiatr Scand. 1983;67:361–70.
40. Costantini M, Musso M, Viterbori P, Bonci F, Del Mastro L, Garrone O, et al.
Detecting psychological distress in cancer patients: validity of the Italian
version of the Hospital Anxiety and Depression Scale. Support Care Cancer.
1999;7:121–7.
41. Stineman MG, Jette A, Fiedler R, Granger C. Impairment-specific dimensions
within the Functional Independence Measure. Arch Phys Med Rehabil.
1997;78:636–43.
42. Solari A, Filippini G, Gasco P, Colla L, Salmaggi A, La Mantia L, et al. Physical
rehabilitation has a positive effect on disability in multiple sclerosis patients.
Neurology. 1999;52:57–62.
43. Ponzio M, Gerzeli S, Brichetto G, Bezzini D, Mancardi GL, Zaratin P, et al.
Economic impact of multiple sclerosis in Italy: focus on rehabilitation costs.
Neurol Sci. 2015;36:227–34. doi: 10.1007/s10072-014-1925-z.
44. Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary
scales: a user’s manual. Boston: The Health Institute, New England Medical
Centre; 1994.
45. Apolone G, Mosconi P. The Italian SF-36 Health Survey: translation, validation
and norming from a clinical epidemiology perspective. J Clin Epidemiol.
1998;51:1025–36.
46. Hérbert R, Bravo G, Préville M. Reliability, validity, and reference values of the
Zarit Burden Interview for assessing informal caregivers of community-dwelling
older persons with dementia. Can J Aging. 2000;19:494–507.
47. Chattat R, Cortesi V, Izzicupo F, Del Re ML, Sgarbi C, Fabbo A, et al. The
Italian version of the zarit burden interview: a validation study. Int
Psychogeriatr. 2010;16:1–9.
48. Diggle P, Heagerty P, Liang KY, Zeger S. Analysis of longitudinal data.
Oxford: Oxford University Press; 2002.
49. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New
York: Springer; 2000.
50. Denzin NK, Lincoln YS. Handbook of qualitative research. London: Sage
Publications; 2000.
51. Crabtree BF, Miller WL. Doing qualitative research. London: Sage
Publications; 1992.
52. Silverman D. Interpreting qualitative data. London: Sage Publications; 1993.
53. McCracken G. The long interview. London: Sage Publications; 1988.
54. Mays N, Pope C. Qualitative research in health care: assessing quality in
qualitative research. BMJ. 2000;320:50–2.
55. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Medical
research council guidance: developing and evaluating complex interventions:
the new medical research council guidance. BMJ. 2008;337:a1655.
56. Pietrolongo E, Giordano A, Kleinefeld M, Confalonieri P, Lugaresi A, Tortorella C,
et al. Decision-making in multiple sclerosis consultations in Italy: third observer
and patient assessments. PLoS One. 2013;8:e60721. doi:10.1371/
journal.pone.0060721.
57. Turner-Stokes L, Sykes N, Silber E, Khatri A, Sutton L, Young E. From
diagnosis to death: exploring the interface between neurology,
rehabilitation and palliative care in managing people with long-term
neurological conditions. Clin Med. 2007;7:129–36.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
